Abstract
Measurements of the insulin-like growth factors (IGFs) and the IGF binding proteins (IGFBPs) have considerable value in diagnosing disease and in assessing the clinical status of patients with known diagnoses. This chapter reviews applications of these measurements and provides an overview of their clinical utility.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ranke MB, Blum WF, Bierich JR. Clinical relevance of serum measurements of insulin-like growth factors and somatomedin binding proteins. Acta Paediatr Scand (Suppl) 1988; 347: 114–126.
Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. Insulin-like growth factors I and II in evaluation of fetal growth retardation. J Pediatr 1986; 109: 428–433.
Underwood LE and Van Wyk JJ. Normal and Aberrant Growth, in Williams Textbook of Endocrinology (Foster DW, Wilson JP,), 8th Ed. Philadelphia, WB Saunders, 1991; pp. 1079–1138.
Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993; 76: 1610–1616.
Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J, Shakkebaek NE. Serum levels of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) in healthy infants, children and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534–2542.
Underwood LE, Smith EP, Van Wyk JJ, Clemmons DR, D’ Ercole AJ, Pandian MR, Preece MA, Moore WV. Somatomedin-C/Insulin-like growth factor I: regulation and clinical applications. In: Raiti S and Tolman RA (eds), Human Growth Hormone, Plenum Publishing, New York, pp. 609–619.
Hasegawa Y, Hasegawa T, Aso T, et al. Comparison between insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) measurement in the diagnosis of growth hormone deficiency. Endocr J 1996; 40: 185–190.
Nunez SB, Municchi G, Barnes KM, Rose SR. Insulin-like growth factor I (IGF-I) and IGF binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children: a clinical research center study. J Clin Endocrinol Metab 1996; 81: 1927–1932.
Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, Melmed S, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA. Diagnosis of growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80: 1532–1540.
Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, Rasmussen S, Muller J, Shakkebaek NE. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 2497–2502.
Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. Insulin-like growth factors I and II in the evaluation of growth retardation. J Pediatr 1986; 109: 428–433.
Smith WJ, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR. Use of insulin-like growth factor binding protein-2 (IGFBP-2), IGFBP-3 and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 1993; 77: 1294–1299.
Rasat R, Livesey JL, Espiner EA, Abbott GD, Donald RA. IGF-I and IGFBP-3 screening for disorders of growth hormone secretion. New Zealand Med J 1996; 109: 156–159.
Baxter RC: Editorial. The binding proteins’ binding protein-clinical applications of acid-labile subunit (ALS) measurement. J Clin Endocrinol Metab 1997; 82: 3941–3943.
Khosravi MJ, Diamondi A, Mistry J, Krishna RG, Khare A. Acid-labile subunit of human insulin-like growth factor-binding protein complex: measurement, molecular and clinical evaluation. J Clin Endocrinol Metab 1997; 82: 3944–3951.
Mohnike K, Kluba U, Blum WF, Aumann V, Vorwek P, Mittler U. Serum concentrations of insulin-like growth factors (IGF-I) and IGF-II and IGF binding proteins (IGFBP)-2 and IGFBP-3 in 49 children with ALL, NHL or solid tumors. Klin Padiatr 1995; 207: 225–229.
Baum HBA, Biller BM, Katznelson L, Oppenheim DS, Clemmons DR, Cannistraro KB, Schoenfeld DA, Best SA, Klibanski A. Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81: 84–92.
Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996; 134: 352–356.
Thissen J-P, Ketelslegers J-M, Maiter D. Use of insulin-like growth factor I (IGF-I) and IGF binding protein-3 in the diagnosis of acromegaly and growth hormone deficiency in adults. Growth Regul 1996; 6: 222–229.
Hoffman DM, O’Sullivan AJ, Baxter RC, Ho KKY. Diagnosis of growth hormone deficiency in adults. Lancet 1994; 343: 1064–1068.
Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone secretion. Clin Endocrinol 1995; 42: 425–430.
Svensson J, Johannsson G, and Bengtsson BA. Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol 1997; 46: 579–586.
Skjaerbaek C, Vahl N, Frystyk J, Hansen TB, Jorgensen JO, Hagen C, Chriastiansen JS, Orskov H. Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement. Eur J Endocrinol 1997; 137: 132–137.
Adan L, Souberbielle JC, Brauner R. Diagnostic markers of permanent idiopathic growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 353–358.
Melmed S. Acromegaly. N Engl J Med 1990; 322: 966–977.
Clemmons DR, Van Wyk JJ, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301: 1138–1142.
Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly; correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988; 67: 69–73.
Grinspoon S, Clemmons D, Swearingen B, Kllibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995; 80: 927–932.
Wass JAR, Clemmons DR, Underwood LE. Changes in circulating somatomedin-C levels in bromocriptine treated acromegaly. Clin Endocrinol 1982; 17: 369–377.
Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WE, Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997; 82: 3187–3191.
Wass JAR. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. J Endocrin 155 (Supp 1), 1997; S17–19.
Paramo C, Andrade OMA, Fluiters E, Luna R, de la Fuente J, Garcia-Mayor RV. Comparative study of insulin-like growth factor-I (IGF-) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly. Metabolism 1997; 46: 494–498.
Grant DB, Hambley J, Becker D, Pimstone BL. Reduced sulphation factor in undernourished children. Arch Dis Child 1973; 48: 596–600.
Hintz RL, Suskind R, Amatayakul K, Thanangkul O, Olson R. Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. J Pediatr 1978; 92: 153–156.
Soliman AT, Hassan AE, Aref MK, Hintz RL, Rosenfeld RG, Rogol AD. Serum insulin-like growth factor I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation. Pediatr Res 1986; 20: 1122 1130.
Smith SR, Egar PJ, Pozefsky T, Chhetri MK, Prout TE. Growth hormone in adults with protein calorie malnutrition. Endocrinology 1974; 39: 53–62.
Rappaport R, Prevot C, Czernichow P. Somatomedin activity and growth hormone secretion. I. Changes related to body weight in anorexia nervosa. Acta Paediatr Scand 1980; 69: 37–41.
Tanaka T, Maesaka H, and Suwa S. Changes in somatomedin activity in anorexia nervosa. Endocrinol Jpn 1985; 32: 891–897.
Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB Jr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 1992; 75: 762–767.
Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 1986; 91: 830–836.
Lecornu M, David L, and Francois R. Low serum somatomedin activity in celiac disease. Helv Paediat Acta 1978; 33: 509–516.
Clemmons DR, Klibanski A, Underwood LE, McArthur JW, Ridgway EC, Beitins IZ, Van Wyk JJ. Reduction of plasma immunoreactive somatomedin-C during fasting in humans. J Clin Endocrinol Metab 1981; 53: 1247–1250.
Isley WL, Underwood LE and Clemmons DR. Dietary components that regulate serum somatomedinC concentrations in humans. J Clin Invest 1983; 71: 175–182.
Isley WL, Underwood LE, Clemmons DR. Changes in plasma somatomedin-C in response to ingestion of diets with variable protein and energy content. JPEN 1984; 8: 407–411.
Snyder DK, Clemmons DR, Underwood LE. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans. J Clin Endocrinol Metab 1989; 69: 745–752.
Clemmons DR, Seek MM, Underwood LE. Supplemental essential aminoacids augment the somatomedin-C/insulin-like growth factor-I response to refeeding after fasting. Metabolism 1985; 34: 391–395.
Unterman TG, Vazquez RM, Sla AJ, Martyn PA, Phillips LS. Nutrition and somatomedin. XII. Usefulness of somatomedin-C in nutritional assessment. Am J Med 1985; 78: 228–234.
Donahue SP, Phillips LS. Response of IGF-I to nutritional support in malnourished hospital patients: a possible indicator of short-term changes in nutritional status. Am J Clin Nutr 1989; 50: 962–969.
Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G. Insulin-like growth factor-I: a good indicator of a functional hepatocellular capacity in alcoholic liver cirrhosis. J Endocrinol Invest 1991; 14: 317, 321.
Caregaro L, Alberino F, Amodio P, Merkel C, Angeli P, Plebani M, Bolognesi M, Gatta A. Nutritional and prognostic significance of insulin-like growth factor I in patients with liver cirrhosis. Nutrition 1997; 13: 185–190.
Takano K, Hall K, Kastrup KW, Hizuka N, Shizume K, Kawai K, Akimoto M, Takuma T, Sugino N. Serum somatomedin A in chronic renal failure. J Clin Endocrinol Metab 1979; 48: 371–376.
Goldberg AC, Trivedi B, Delmez JA, Harter HR, Daughaday WH. Uremia reduces serum insulin-like growth factor-I, increases insulin-like growth factor-II, and modified their serum protein binding. J Clin Endocrinol Metab 1982; 55: 1040–1045.
Vehe KL, Brown RO, Moore LW, Acchiardo SR, Luther RW. The efficacy of nutrition support in infected patients with chronic renal failure. Pharmacotherapy 1991; 11: 303–307.
Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) on IGF binding protein in children and adults. J Clin Endocrinol Metab 1995; 80: 443–449.
Clemmons DR, Thissen J-P, Maes M, Ketelslegers JM, Underwood LE. Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF binding proteins in serum. Endocrinology 1989; 125: 2967–2972.
Clemmons DR, Busby WH, Snyder DK. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991; 73: 727–733.
Busby WH, Snyder DK, Clemmons DR. Radioimmunoassay of a 26,000 dalton plasma insulin-like growth factor binding protein: control by nutritional variables. J Clin Endocrinol Metab 1988; 67: 1225–1230.
Baxter RC, Cowell CT. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987; 65: 432–440.
Snyder DK, Clemmons DR. Insulin dependent regulation of IGFBP-I. J Clin Endocrinol Metab 1991; 71: 1532–1636.
Cohick WS, McGuire MA, Clemmons DR, Bauman DE. Regulation of IGF binding proteins in serum, and lymph of lactating cows by somatotropin. Endocrinology 1992; 130: 1508–1514.
Smith WJ, Underwood LE, Keyes L, Clemmons DR. Use of insulin-like growth factor I (IGF-I) and IGFbinding protein measurements to monitor feeding of premature infants. J Clin Endocrinol Metab 1997; 82: 3982–3988.
Pucilowska JB, Davenport ML, Kabir I, Clemmons DR, Thissa JP, Butler T, Underwood LE. The effect of dietary protein supplementation on IGFs and IGFBPs in children with Shigellosis. J Clin Endocrinol Metab 1993; 77: 1516–1521.
Ismail IS, Miell JP, Scanlon MF, Peters JR. Effects of cholinergic modulation on serum insulin-like growth factor-I and its binding proteins in normal and diabetic subjects. Clin Endocrinol 1995; 42: 147–152.
Tapanainen P, Kaar ML, Leppaluoto J, Huttunen NP, Knip M. Normal stimulated growth hormone secretion but low peripheral levels of insulin-like growth factor I in prepubertal children with insulin-dependent diabetes mellitus. Acta Paediatr 1995; 84: 6546–6650.
Hilding A, Brismar K, Degerglad M, Thoren M, Hall K. Altered relation between circulating levels of insulin-like growth factor binding protein-1 and insulin in growth hormone deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646–2652.
Bereket A, Lang CH, Blethen SL, Wilson TA. Insulin-like growth factor binding protein-2 and insulin: studies in children with type I diabetes mellitus and maturity-onset diabetes of the young. J Clin Endocrinol Metab 1995; 80: 3647–3652.
Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and non-obese humans. J Clin Endocrinol Metab 1992; 74: 1355–1360.
Bang P, Brismar K, Rosenfeld RG, Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding protein differently in patients with noninsulin-dependent diabetes mellitus versus healthy and nonobese and obese subjects. J Clin Endocrinol Metab 1994; 78: 960–967.
Jorgensen JO, Pedersen SB, Borglum J, Frystyk J, Ho KK, Christiansen JS, Orskov H, Blum WF, Richelsen B. Serum concentrations of insulin-like growth factors (IGFs), IGF binding proteins 1 and 3 and growth hormone binding protein in obese women and the effects of growth hormone administration: a double-blind, placebo-controlled study. Eur J Endocrinol 1995; 133: 65–70.
Lee PDK, Conver CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 1993; 204: 4–29.
Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc Soc Exptl Biol Med 1997; 216: 319–357.
Baxter RC. Insulin-like growth factor binding proteins as glucoregulators. Metabolism 1995; 44: 12–17.
Mogul HR, Marshall M, Frey M, Burke HB, Wynn PS, Wilker S, Southern AL, Gambert SR. Insulin-like growth factor binding protein-1 as a market for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab 1996; 81: 4492–4495.
Gibson JM, Westwood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996; 81: 860–863.
Levitt-Katz LE, Satin-Smith MS, Collett-Solberg P, Thornton PS, Baker L, Stanley CA, Cohen P. Insulin-like growth factor binding protein-I in the diagnosis of hypoglycemia caused by hyperinsulinism. J Pediatr 1997; 131: 193–199.
Froesch ER and ZapfJ. Tumor hypoglycemia and various forms of nonsuppressible insulin-like activity. In: Andreani D, Lefebvre PJ, and Marks V, eds., Current Views on Hypoglycemia and Glycogen, Academic Press, New York, 1980; 163–171.
ZapfJ, Schoenle EJ, Waldvogel M, Sand I, Froesch ER. Effect of trypsin-treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors. Further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 1981; 113: 605–609.
Daughaday WH, Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci USA 1989; 86: 6778–6782.
Daughaday WH, Trivedi B, and Baxter RC. Serum “big insulin-like growth factor IP” from patients with tumor hypoglycemia lacks normal E-domain 0-linked glycosylation, a possible determinant of normal propeptide processing. Proc Natl Acad Sci USA 1993; 90: 5823–5827.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–566.
Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin like growth factor binding protein-2 in prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031 1035.
Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A. Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostatic cancer: correlation with serum prostate specific antigen. J Clin Endocrinol Metab 1993; 77: 229–233.
Ho PJ and Baxter RC. Insulin-like growth factor binding Protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 1997; 46: 333–342.
Cotterill AM, Holly JM, Taylor AM, Davies SC, Coulson VJ, Preece MA, Wass JA, Savage MO. The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism. J Clin Endocrinol Metab 1992; 74: 56–63.
Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z. Long term treatment of Laron type dwarfs with insulin-like growth factor-I increases serum insulin-like growth factor binding protein-3 in the absence of growth hormone activity. Acta Endocrinol (Copenh) 1993; 128: 144–149.
Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, Chatelain PG, Preece MA, Rosenfeld RG. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993; 77: 1465–1471.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Underwood, L.E. (1999). Clinical Uses of IGF-I and IGF Binding Protein Assays. In: Rosenfeld, R.G., Roberts, C.T. (eds) The IGF System. Contemporary Endocrinology, vol 17. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-712-3_25
Download citation
DOI: https://doi.org/10.1007/978-1-59259-712-3_25
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-138-7
Online ISBN: 978-1-59259-712-3
eBook Packages: Springer Book Archive